Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
FASEB J. 2020 Oct;34(10):13877-13884. doi: 10.1096/fj.202001700RR. Epub 2020 Aug 28.
The diagnosis of COVID-19 requires integration of clinical and laboratory data. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic assays play a central role in diagnosis and have fixed technical performance metrics. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. Our goal was to examine the clinical sensitivity of two most common SARS-CoV-2 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the disease course to provide insight into their clinical interpretation in patients presenting to the hospital. We conducted a single-center, retrospective study. To derive clinical sensitivity of PCR, we identified 209 PCR-positive SARS-CoV-2 patients with multiple PCR test results (624 total PCR tests) and calculated daily sensitivity from date of symptom onset or first positive test. Clinical sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity during the first 5 days after symptom onset, 70%-71% from Days 9 to 11, and 30% at Day 21. To calculate daily clinical sensitivity by serology, we utilized 157 PCR-positive patients with a total of 197 specimens tested by enzyme-linked immunosorbent assay for IgM, IgG, and IgA anti-SARS-CoV-2 antibodies. In contrast to PCR, serological sensitivity increased with days post symptom onset with >50% of patients seropositive by at least one antibody isotype after Day 7, >80% after Day 12, and 100% by Day 21. Taken together, PCR and serology are complimentary modalities that require time-dependent interpretation. Superimposition of sensitivities over time indicate that serology can function as a reliable diagnostic aid indicating recent or prior infection.
COVID-19 的诊断需要整合临床和实验室数据。严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)诊断检测在诊断中起着核心作用,具有固定的技术性能指标。由于病毒清除和免疫反应的出现,临床敏感性发生变化,因此解释变得具有挑战性。我们的目标是研究两种最常见的 SARS-CoV-2 诊断检测方法聚合酶链反应(PCR)和血清学在疾病过程中的临床敏感性,以深入了解它们在就诊于医院的患者中的临床解释。我们进行了一项单中心回顾性研究。为了得出 PCR 的临床敏感性,我们确定了 209 例 PCR 阳性 SARS-CoV-2 患者,这些患者有多次 PCR 检测结果(总共 624 次 PCR 检测),并从症状出现或首次阳性检测之日起计算每日敏感性。PCR 的临床敏感性随症状出现后的天数而降低,症状出现后的前 5 天内有超过 90%的临床敏感性,第 9 至 11 天为 70%-71%,第 21 天为 30%。为了通过血清学计算每日临床敏感性,我们利用了 157 例 PCR 阳性患者,总共对 197 份标本进行了酶联免疫吸附试验,检测 IgM、IgG 和 IgA 抗 SARS-CoV-2 抗体。与 PCR 相反,血清学敏感性随症状出现后的天数而增加,至少有一种抗体同种型呈阳性的患者超过 50%在第 7 天之后,超过 80%在第 12 天之后,第 21 天 100%呈阳性。总的来说,PCR 和血清学是互补的检测方法,需要进行时间依赖性解释。敏感性随时间的叠加表明,血清学可以作为一种可靠的诊断辅助手段,表明近期或既往感染。